Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma

Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous ca...

Full description

Saved in:
Bibliographic Details
Published in:Experimental hematology & oncology 2022-10, Vol.11 (1), p.1-78, Article 78
Main Authors: Ma, Rong, Wang, Jia-Lin, Wang, Yan-Yang
Format: Article
Language:English
Subjects:
Apoptosis
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Complications and side effects
Correspondence
Development and progression
Endothelium
Immunoglobulin G
Liver cancer
Lung cancer
Medical imaging
Metastasis
Patients
Pneumonia
Radiation
Radiation therapy
Radiotherapy
Reactive cutaneous capillary endothelial proliferation (RCCEP)
Recall
Squamous cell carcinoma
Stereotactic body radiation therapy (SBRT)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c504t-1d49fa6c353bcb4dfeaede16669502879cf594c3273055886e0dc7076923ce363
cites cdi_FETCH-LOGICAL-c504t-1d49fa6c353bcb4dfeaede16669502879cf594c3273055886e0dc7076923ce363
container_end_page 78
container_issue 1
container_start_page 1
container_title Experimental hematology & oncology
container_volume 11
creator Ma, Rong
Wang, Jia-Lin
Wang, Yan-Yang
description Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event in camrelizumab-treated patients. Here, we introduce a case of LSCC with recall RCCEP induced by stereotactic body radiation therapy (SBRT). A 76-year-old LSCC patient developed RCCEP when he received camrelizumab and chemotherapy. After discontinuing camrelizumab treatment, the RCCEP lesions spontaneously regressed and fell off. However, when the patient received subsequent SBRT, the RCCEP occurred again at the same sites. This case may provide clues for additional study of the immune reactivation effect of SBRT or the underlying mechanism of RCCEP.
doi_str_mv 10.1186/s40164-022-00336-4
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cddb3b4ccf6c4cccb688ce5baf545843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A724197248</galeid><doaj_id>oai_doaj_org_article_cddb3b4ccf6c4cccb688ce5baf545843</doaj_id><sourcerecordid>A724197248</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-1d49fa6c353bcb4dfeaede16669502879cf594c3273055886e0dc7076923ce363</originalsourceid><addsrcrecordid>eNpdkl1rFDEUhgdRsNT-Aa8CgqwXU_M1mcyNUJdaCwVlrdchk5zZzZKdTJOZyv4o_6OZnSLWXJyE5M3Dez6K4i3Bl4RI8TFxTAQvMaUlxoyJkr8ozigRtGSCNC__Ob8uLlLa47wEFZLUZ8XvDRjtPQodiqDN6B4BmWnUPYQpIaMH572ORwS9DeMOvNMeDTF410HUows9Wm3W6-vvH5Dr7WTAovaI0ggRwjjjDGqDPaKorVvkGRL1cESrH5839_MvpNGQn6Af0S837pCf-i1KD5M-nBxANmd0NK4PB_2meNVpn-DiaT8vfn65vl9_Le--3dyur-5KU2E-lsTyptPCsIq1puW2Aw0WiBCiqTCVdWO6quGG0ZrhqpJSALamxrVoKDPABDsvbheuDXqvhugOuQYqaKdOFyFulY45OQ_KWNuylhvTCZOjaYWUBqpWdxWvJGeZ9WlhDVN7AGtyolH7Z9DnL73bqW14VI3AtaxmM6snQAwPE6RRHVya67I0SdGaNhXhDWuy9N1_0n2YYp9LlVWslphJPAPfL6qtzgnsQPtxl4Kf5v4kdVVTTpocZBbSRWhiSClC99c1wWoePbWMnsqjp06jpzj7AzR2z0A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2737803806</pqid></control><display><type>article</type><title>Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Ma, Rong ; Wang, Jia-Lin ; Wang, Yan-Yang</creator><creatorcontrib>Ma, Rong ; Wang, Jia-Lin ; Wang, Yan-Yang</creatorcontrib><description>Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event in camrelizumab-treated patients. Here, we introduce a case of LSCC with recall RCCEP induced by stereotactic body radiation therapy (SBRT). A 76-year-old LSCC patient developed RCCEP when he received camrelizumab and chemotherapy. After discontinuing camrelizumab treatment, the RCCEP lesions spontaneously regressed and fell off. However, when the patient received subsequent SBRT, the RCCEP occurred again at the same sites. This case may provide clues for additional study of the immune reactivation effect of SBRT or the underlying mechanism of RCCEP.</description><identifier>ISSN: 2162-3619</identifier><identifier>EISSN: 2162-3619</identifier><identifier>DOI: 10.1186/s40164-022-00336-4</identifier><language>eng</language><publisher>London: BioMed Central Ltd</publisher><subject>Apoptosis ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Complications and side effects ; Correspondence ; Development and progression ; Endothelium ; Immunoglobulin G ; Liver cancer ; Lung cancer ; Medical imaging ; Metastasis ; Patients ; Pneumonia ; Radiation ; Radiation therapy ; Radiotherapy ; Reactive cutaneous capillary endothelial proliferation (RCCEP) ; Recall ; Squamous cell carcinoma ; Stereotactic body radiation therapy (SBRT)</subject><ispartof>Experimental hematology &amp; oncology, 2022-10, Vol.11 (1), p.1-78, Article 78</ispartof><rights>COPYRIGHT 2022 BioMed Central Ltd.</rights><rights>2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-1d49fa6c353bcb4dfeaede16669502879cf594c3273055886e0dc7076923ce363</citedby><cites>FETCH-LOGICAL-c504t-1d49fa6c353bcb4dfeaede16669502879cf594c3273055886e0dc7076923ce363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607856/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2737803806?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25730,27900,27901,36988,36989,38492,43870,44565,53765,53767</link.rule.ids></links><search><creatorcontrib>Ma, Rong</creatorcontrib><creatorcontrib>Wang, Jia-Lin</creatorcontrib><creatorcontrib>Wang, Yan-Yang</creatorcontrib><title>Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma</title><title>Experimental hematology &amp; oncology</title><description>Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event in camrelizumab-treated patients. Here, we introduce a case of LSCC with recall RCCEP induced by stereotactic body radiation therapy (SBRT). A 76-year-old LSCC patient developed RCCEP when he received camrelizumab and chemotherapy. After discontinuing camrelizumab treatment, the RCCEP lesions spontaneously regressed and fell off. However, when the patient received subsequent SBRT, the RCCEP occurred again at the same sites. This case may provide clues for additional study of the immune reactivation effect of SBRT or the underlying mechanism of RCCEP.</description><subject>Apoptosis</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Complications and side effects</subject><subject>Correspondence</subject><subject>Development and progression</subject><subject>Endothelium</subject><subject>Immunoglobulin G</subject><subject>Liver cancer</subject><subject>Lung cancer</subject><subject>Medical imaging</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Pneumonia</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Reactive cutaneous capillary endothelial proliferation (RCCEP)</subject><subject>Recall</subject><subject>Squamous cell carcinoma</subject><subject>Stereotactic body radiation therapy (SBRT)</subject><issn>2162-3619</issn><issn>2162-3619</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkl1rFDEUhgdRsNT-Aa8CgqwXU_M1mcyNUJdaCwVlrdchk5zZzZKdTJOZyv4o_6OZnSLWXJyE5M3Dez6K4i3Bl4RI8TFxTAQvMaUlxoyJkr8ozigRtGSCNC__Ob8uLlLa47wEFZLUZ8XvDRjtPQodiqDN6B4BmWnUPYQpIaMH572ORwS9DeMOvNMeDTF410HUows9Wm3W6-vvH5Dr7WTAovaI0ggRwjjjDGqDPaKorVvkGRL1cESrH5839_MvpNGQn6Af0S837pCf-i1KD5M-nBxANmd0NK4PB_2meNVpn-DiaT8vfn65vl9_Le--3dyur-5KU2E-lsTyptPCsIq1puW2Aw0WiBCiqTCVdWO6quGG0ZrhqpJSALamxrVoKDPABDsvbheuDXqvhugOuQYqaKdOFyFulY45OQ_KWNuylhvTCZOjaYWUBqpWdxWvJGeZ9WlhDVN7AGtyolH7Z9DnL73bqW14VI3AtaxmM6snQAwPE6RRHVya67I0SdGaNhXhDWuy9N1_0n2YYp9LlVWslphJPAPfL6qtzgnsQPtxl4Kf5v4kdVVTTpocZBbSRWhiSClC99c1wWoePbWMnsqjp06jpzj7AzR2z0A</recordid><startdate>20221026</startdate><enddate>20221026</enddate><creator>Ma, Rong</creator><creator>Wang, Jia-Lin</creator><creator>Wang, Yan-Yang</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221026</creationdate><title>Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma</title><author>Ma, Rong ; Wang, Jia-Lin ; Wang, Yan-Yang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-1d49fa6c353bcb4dfeaede16669502879cf594c3273055886e0dc7076923ce363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Apoptosis</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Complications and side effects</topic><topic>Correspondence</topic><topic>Development and progression</topic><topic>Endothelium</topic><topic>Immunoglobulin G</topic><topic>Liver cancer</topic><topic>Lung cancer</topic><topic>Medical imaging</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Pneumonia</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Reactive cutaneous capillary endothelial proliferation (RCCEP)</topic><topic>Recall</topic><topic>Squamous cell carcinoma</topic><topic>Stereotactic body radiation therapy (SBRT)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Rong</creatorcontrib><creatorcontrib>Wang, Jia-Lin</creatorcontrib><creatorcontrib>Wang, Yan-Yang</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Experimental hematology &amp; oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Rong</au><au>Wang, Jia-Lin</au><au>Wang, Yan-Yang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma</atitle><jtitle>Experimental hematology &amp; oncology</jtitle><date>2022-10-26</date><risdate>2022</risdate><volume>11</volume><issue>1</issue><spage>1</spage><epage>78</epage><pages>1-78</pages><artnum>78</artnum><issn>2162-3619</issn><eissn>2162-3619</eissn><abstract>Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event in camrelizumab-treated patients. Here, we introduce a case of LSCC with recall RCCEP induced by stereotactic body radiation therapy (SBRT). A 76-year-old LSCC patient developed RCCEP when he received camrelizumab and chemotherapy. After discontinuing camrelizumab treatment, the RCCEP lesions spontaneously regressed and fell off. However, when the patient received subsequent SBRT, the RCCEP occurred again at the same sites. This case may provide clues for additional study of the immune reactivation effect of SBRT or the underlying mechanism of RCCEP.</abstract><cop>London</cop><pub>BioMed Central Ltd</pub><doi>10.1186/s40164-022-00336-4</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2162-3619
ispartof Experimental hematology & oncology, 2022-10, Vol.11 (1), p.1-78, Article 78
issn 2162-3619
2162-3619
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cddb3b4ccf6c4cccb688ce5baf545843
source Publicly Available Content Database; PubMed Central; Coronavirus Research Database
subjects Apoptosis
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Complications and side effects
Correspondence
Development and progression
Endothelium
Immunoglobulin G
Liver cancer
Lung cancer
Medical imaging
Metastasis
Patients
Pneumonia
Radiation
Radiation therapy
Radiotherapy
Reactive cutaneous capillary endothelial proliferation (RCCEP)
Recall
Squamous cell carcinoma
Stereotactic body radiation therapy (SBRT)
title Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T23%3A25%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recall%20of%20reactive%20cutaneous%20capillary%20endothelial%20proliferation%20(RCCEP)%20induced%20by%20stereotactic%20body%20radiation%20therapy%20(SBRT)%20in%20a%20patient%20with%20lung%20squamous%20cell%20carcinoma&rft.jtitle=Experimental%20hematology%20&%20oncology&rft.au=Ma,%20Rong&rft.date=2022-10-26&rft.volume=11&rft.issue=1&rft.spage=1&rft.epage=78&rft.pages=1-78&rft.artnum=78&rft.issn=2162-3619&rft.eissn=2162-3619&rft_id=info:doi/10.1186/s40164-022-00336-4&rft_dat=%3Cgale_doaj_%3EA724197248%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c504t-1d49fa6c353bcb4dfeaede16669502879cf594c3273055886e0dc7076923ce363%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2737803806&rft_id=info:pmid/&rft_galeid=A724197248&rfr_iscdi=true